$15.52
+0.92 (+6.30%)
Open$14.85
Previous Close$14.60
Day High$16.24
Day Low$14.27
52W High$10.35
52W Low$5.54
Volume—
Avg Volume793.7K
Market Cap132.22M
P/E Ratio—
EPS$-0.53
SectorBiotechnology
Analyst Ratings
Buy
16 analysts
Price Target
-40.7% upside
Current
$15.52
$15.52
Target
$9.21
$9.21
$5.69
$9.21 avg
$10.08
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 25.44M | 26.00M | 21.24M |
| Net Income | 806.3K | 1.01M | 706.3K |
| Profit Margin | 3.2% | 3.9% | 3.3% |
| EBITDA | 1.35M | 1.64M | 1.18M |
| Free Cash Flow | 550.9K | 646.8K | 654.2K |
| Rev Growth | +11.4% | +22.0% | +10.8% |
| Debt/Equity | 0.16 | 0.17 | 0.16 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |